Emotional Blunting in Depression in the PREDDICT Clinical Trial: Inflammation-Stratified Augmentation of Vortioxetine With Celecoxib.
Emma SampsonErhan KavakbasiNatalie T MillsHikaru HoriKlaus Oliver SchubertCélia FourrierBernhard T BaunePublished in: The international journal of neuropsychopharmacology (2024)
This analysis suggests favorable effects of vortioxetine on emotional blunting in both short- and long-term course. The beneficial impact of vortioxetine on emotional blunting was weaker in celecoxib-augmented patients compared with placebo, possibly due to pharmacokinetic interactions. Clinical Trials Registration: Australian New Zealand Clinical Trials Registry (ANZCTR), ACTRN12617000527369p. Registered on 11 April 2017, http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12617000527369p.
Keyphrases
- clinical trial
- phase iii
- major depressive disorder
- phase ii
- double blind
- end stage renal disease
- study protocol
- open label
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- oxidative stress
- depressive symptoms
- physical activity
- randomized controlled trial
- patient reported
- quantum dots
- virtual reality